Vectura Group plc release: Phase III data show NVA237 significantly improves lung function with good safety profile in COPD patients.

Vectura Group plc (Vectura) has announced that NVA237, a long-acting muscarinic antagonist (LAMA) being investigated as a once daily treatment for chronic obstructive pulmonary disease (COPD), achieved its primary endpoint in a Phase III study. As part of 1Q 2011 earnings release, Novartis confirmed results from the first Phase III clinical trial with once-daily NVA237 (glycopyrronium bromide) show that it significantly improved lung function while demonstrating a good safety profile in patients with moderate-to-severe COPD. The pivotal double-blind 26-week GLOW1 study met its primary endpoint by demonstrating superior bronchodilation to placebo at 12 weeks measured by trough FEV1 …